selinexor (Rx)

Brand and Other Names:Xpovio
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 20mg

Multiple Myeloma

Indicated in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody

80 mg PO plus dexamethasone 20 mg PO on Days 1 and 3 of each week

Continue until disease progression or unacceptable toxicity

Diffuse Large B-Cell Lymphoma

Indicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, in patients previously treated with at least 2 lines of systemic therapy

60 mg PO on Days 1 and 3 of each week

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Dosage reduction recommendations for adverse effects

  • RRMM
    • Starting dose: 80 mg on Days 1 and 3 each week (160 mg/week)
    • First reduction: 100 mg once weekly
    • Second reduction: 80 mg once weekly
    • Third reduction: 60 mg once weekly
    • Fourth reduction: Permanently discontinue
  • DLBCL
    • Starting dose: 60 mg on Days 1 and 3 each week (120 mg/week)
    • First reduction: 40 mg Days 1 and 3 of each week (80 mg total per week)
    • Second reduction: 60 mg once weekly
    • Third reduction: 40 mg once weekly
    • Fourth reduction: Permanently discontinue

Thrombocytopenia (RRMM)

  • Platelet count 25,000-75,000/mcL: Reduce by 1 dose level
  • Platelet count 25,000-75,000/mcL with bleeding: Interrupt dosing; restart at 1 dose level lower after bleeding resolved
  • Platelet count <25,000/mcL: Interrupt dosing; monitor until platelet count returns to ≥50,000/mcL, then restart at 1 dose level lower

Thrombocytopenia (DLBCL)

  • Platelet count 50,000 to <75,000/mcL: Interrupt 1 dose; restart at the same dose level
  • Platelet count 25,000 to <50,000/mcL without bleeding
    • First occurrence: Interrupt dose; monitor until platelet count returns to ≥50,000/mcL
    • Reduce by 1 dose level
  • Platelet count 25,000 to <50,000/mcL with concurrent bleeding
    • Interrupt dose; monitor until platelet count returns to ≥50,000/mcL
    • Restart at 1 dose level lower, after bleeding has resolved
    • Administer platelet transfusions per clinical guidelines
  • Platelet count <25,000/mcL
    • Interrupt dose; monitor until platelet count returns to ≥50,000/mcL
    • Restart at 1 dose level lower
    • Administer platelet transfusions per clinical guidelines

Neutropenia (RRMM)

  • ANC 0.5-1 x 109/L without fever: Reduce by 1 dose level
  • ANC <0.5 x 109/L or febrile neutropenia: Interrupt dosing; monitor until neutrophil count returns to ≥1 x 109/L, then restart at 1 dose level lower

Neutropenia (DLBCL)

ANC 0.5 to <1 x 10^9/L without fever
  • First occurrence: Interrupt dose; monitor until neutrophil counts return to ≥1 x 109/L; restart at the same dose level
  • Recurrence: Interrupt dose; monitor until neutrophil counts return to ≥1 x 109/L; administer growth factors per clinical guidelines; restart at 1 dose level lower
  • ANC <0.5 x 109/L or febrile neutropenia: Interrupt dosing; monitor until neutrophil count returns to ≥1 x 109/L; administer growth factors per clinical guidelines; restart at 1 dose level lower

Anemia

  • Hemoglobin <8 g/dL: Reduce by 1 dose level; administer blood transfusion and/or other treatments per clinical guidelines
  • Life-threatening consequences (urgent intervention indicated): Interrupt dosing; monitor until hemoglobin ≥8 g/dL, then restart at 1 dose level lower; administer blood transfusion and/or other treatments per clinical guidelines

Hyponatremia

  • Serum sodium <130 mmol/L: Interrupt dosing and provide supportive care
  • Monitor until sodium returns to ≥130 mmol/L
  • Restart at 1 dose level lower

Fatigue

  • Grade 2 lasting >7 days or Grade 3: Interrupt dosing
  • Monitor until fatigue resolves to Grade 1 or baseline
  • Restart at 1 dose level lower

Nausea & vomiting

  • Grade 1 or 2
    • Grade 1 or 2 nausea (decrease oral intake without significant weight loss, dehydration, or malnutrition) OR
    • Grade 1 or 2 vomiting (≤5 episodes/day)
    • Maintain dose and initiate additional antinausea medications
  • Grade ≥3
    • Grade 3 nausea (inadequate oral caloric or fluid intake) OR
    • Grade ≥3 vomiting (≥6 episodes/day)
    • Interrupt dosing; monitor until nausea/vomiting resolved to ≤Grade 2; initiate additional antinausea medications; restart at 1 dose level lower

Diarrhea

  • Grade 2 (inrease of 4-6 stools/day over baseline): If 1st episode, maintain dose and institute supportive care
  • Grade 2 (2nd and subsequent episodes): Reduce by 1 dose level; institute supportive care
  • Grade ≥3 (increase ≥7 stools/day over baseline; hospitalization indicated): Interrupt dosing and institute supportive care; monitor until resolved to Grade ≤2; restart at 1 dose level lower

Weight loss and anorexia

  • Weight loss of 10-20% or anorexia associated with significant weight loss or malnutrition
  • Interrupt and institute supportive care
  • Monitor until weight returns to >90% baseline
  • Restart at 1 dose level lower

Other nonhematologic adverse effects

  • Grade 3 or 4 (life-threatening)
    • Interrupt dosing
    • Monitor until resolved to Grade ≤2
    • Restart at 1 dose level lower

Renal impairment

  • Mild-to-severe (CrCl 15-89 mL/min): No significant differences in pharmacokinetics observed
  • ESRD (CrCl <15 mL/min) or hemodialysis: Effect on pharmacokinetics unknown

Hepatic impairment

  • Mild: No significant differences in pharmacokinetics observed
  • Moderate-to-severe: Effect on pharmacokinetics unknown

Dosing Considerations

Concomitant treatment

  • Maintain adequate fluid and caloric intake throughout treatment
  • Consider IV hydration for patients at risk of dehydration
  • Provide prophylactic concomitant treatment with a 5–HT3 antagonist and/or other antinausea agents before and during treatment

Monitor parameters

  • Monitor at baseline and as clinically indicated
  • Monitor more frequently during the first 3 months of treatment
  • Assess the need for dosage modifications for adverse reaction
  • CBC with differential
  • Standard blood chemistries
  • Body weight
  • Nutritional status
  • Volume status

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and selinexor

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            • RRMM

            • All grades
              • Thrombocytopenia (74%)
              • Fatigue (73%)
              • Nausea (72%)
              • Anemia (59%)
              • Decreased appetite (53%)
              • Weight decreased (47%)
              • Diarrhea (44%)
              • Vomiting (41%)
              • Hyponatremia (39%)
              • Neutropenia (34%)
              • Leukopenia (28%)
              • Constipation (25%)
              • Dyspnea (24%)
              • Upper respiratory tract infection (21%)
              • Cough (16%)
              • Mental status changes (16%)
              • Pyrexia (16%)
              • Hyperglycemia (15%)
              • Dizziness (15%)
              • Insomnia (15%)
              • Lymphopenia (15%)
              • Dehydration (14%)
              • Hypercreatinemia (14%)
              • Pneumonia (13%)
              • Epistaxis (12%)
              • Hypokalemia (12%)
              • Dysgeusia (11%)
            • Grade 3 or 4
              • Thrombocytopenia (61%)
              • Anemia (40%)
              • Fatigue (22%)
              • Hyponatremia (22%)
              • Neutropenia (21%)
              • Leukopenia (11%)
            • DLBCL

            • All grades
              • Fatigue (63%)
              • Nausea (57%)
              • Diarrhea (37%)
              • Appetite decrease (37%)
              • Weight decrease (30%)
              • Constipation (29%)
              • Vomiting (28%)
              • Pyrexia (22%)
              • Cough (18%)
              • Edema (17%)
              • Upper respiratory tract infection (17%)
              • Dizziness (16%)
              • Musculoskeletal pain (15%)
              • Hypotension (13%)
              • Taste disorder (13%)
              • Mental status changes (11%)
              • Vision blurred (11%)
            • Grade 3 or 4
              • Fatigue (15%)

            1-10%

            • RRMM

            • All grades
              • Blurred vision (10%)
              • Headache (10%)
            • Grade 3 or 4
              • Lymphopenia (10%)
              • Nausea (9%)
              • Pneumonia (9%)
              • Mental status changes (7%)
              • Hyperglycemia (7%)
              • Diarrhea (6%)
              • Decreased appetite (4.5%)
              • Vomiting (3.5%)
              • Dyspnea (3.5%)
              • Dehydration (3.5%)
              • Hypokalemia (3.5%)
              • Upper respiratory tract infection (3%)
              • Insomnia (2%)
              • Hypercreatinemia (2%)
              • Constipation (1.5%)
            • DLBCL

            • All grades
              • Hemorrhage (10%)
              • Abdominal pain (10%)
              • Dyspnea (10%)
              • Pneumonia (10%)
              • Urinary tract infection (10%)
              • Peripheral neuropathy, sensory (10%)
            • Grade 3 or 4
              • Pneumonia (6%)
              • Nausea (6%)
              • Pyrexia (4.5%)
              • Mental status changes (3.7%)
              • Appetite decrease (3.7%)
              • Hypotension (3%)
              • Urinary tract infection (3%)
              • Diarrhea (3%)
              • Musculoskeletal pain (2.2%)
              • Edema (2.2%)
              • Upper respiratory tract infection (1.5%)
              • Vomiting (1.5%)
              • Dyspnea (1.5%)

            <1%

            DLBCL

            Grade 3 or 4
            • Vision blurred (0.7%)
            • Hemorrhage (0.7%)
            • Dizziness (0.7%)
            Previous
            Next:

            Warnings

            Contraindications

            None

            Cautions

            Life-threatening thrombocytopenia, potentially leading to hemorrhage may occur

            Neutropenia commonly reported, potentially increasing infection risk

            Nausea and/or vomiting commonly occurs; follow recommendations for adequate hydration and prophylactic antiemetics

            Diarrhea commonly reported; monitor for dehydration and provide supportive care as required

            Anorexia and weight loss reported

            Hyponatremia may rapidly occur (median onset 8 days) and may be severe

            Infections reported; most infections were not associated with neutropenia and were caused by nonopportunistic organisms

            Neurological toxicity may occur, including dizziness, syncope, depressed level of consciousness, and mental status changes (including delirium and confused state)

            Embryofetal toxicity can occur

            Previous
            Next:

            Pregnancy

            Pregnancy

            Based on animal studies and its mechanism of action, selinexor can cause fetal harm if administered to pregnant women

            Verify pregnancy status of females of reproductive potential before initiating selinexor

            Animal studies

            • Administration to pregnant rats during organogenesis resulted in structural abnormalities and alterations to growth at exposures below those clinically recommended for humans

            Contraception

            • Females of reproductive potential: Use effective contraception during treatment and for 1 week after the last dose
            • Males with female partner of reproductive potential: Use effective contraception during treatment and for 1 week after the last dose

            Infertility

            • Based on animal studies, selinexor may impair fertility in females and males

            Lactation

            No data are available regarding the presence of selinexor or its metabolites in human milk, or their effects on the breastfed child or milk production

            Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 1 week after the last dose

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective inhibitor of nuclear export (SINE) of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1)

            XPO1 inhibition leads to accumulation of TSPs in the nucleus, reductions in several oncoproteins (eg, c–myc, cyclin D1), cell cycle arrest, and apoptosis of cancer cells

            Selinexor demonstrated proapoptotic activity in vitro in multiple myeloma cell lines, patient tumor samples, and murine xenograft model

            Absorption

            Peak plasma time: 4 hr

            Peak plasma concentration

            • 60 mg-dose: 442 ng/mL
            • 80 mg-dose: 680 ng/mL

            AUC

            • 60 mg-dose: 4,096 ng⋅hr/mL
            • 80 mg-dose: 5,386 ng⋅hr/mL

            Distribution

            Vd: 133 L

            Protein bound: 95%

            Metabolism

            Metabolized by CYP3A4, multiple UGTs, and glutathione S-transferases

            Elimination

            Half-life: 6-8 hr

            Clearance: 18.6 L/hr

            Previous
            Next:

            Administration

            Oral Administration

            May take with or without food

            Swallow tablet whole; do not break, chew, crush, or divide

            On scheduled administration day, take tablet at about the same time of day

            Missed, delayed, or vomited dose

            • Take next dose at the next regularly scheduled time
            • Vomited dose: Do not repeat dose; wait until next scheduled dose

            Storage

            Store at or below 30ºC (86ºF)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.